Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label study of BAY 2927088 in advanced EGFR/HER2-mutant NSCLC
NL-OMON53944Phase 1Not yet recruiting
- Sponsor
- Bayer
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sevabertinib in non-small cell lung cancer (NSCLC) (8 arms), sponsored by Bayer. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Maximum tolerated dose or maximum administered dose and 2 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53944.